YektaSonics Inc.

YektaSonics Inc. develops and commercializes patented electronic systems specifically designed for Focused Ultrasound medical devices. The company's core offering includes advanced driving systems for Power Modules and Phased Arrays, which enhance the efficacy and reduce the cost of transducer-based acoustic wave generation. This technology delivers performance advantages such as harmonic-free output, miniaturized circuitry, and precise power control, supporting a broad spectrum of medical and non-medical applications.

Founded in 2015 by Navid Gougol, YektaSonics emerged from the insight that non-invasive therapeutic methods could be significantly advanced through innovative and cost-effective electronic systems. Gougol recognized the potential of Focused Ultrasound to treat a wide array of medical conditions, including complex neurological and oncological issues, without the need for invasive procedures, by optimizing the underlying electronic beamforming technology.

The company primarily serves medical device manufacturers seeking to implement or enhance Focused Ultrasound capabilities across diverse therapeutic areas such as oncology, gynecology, neurology, and psychiatry. YektaSonics envisions a future where its electronic systems enable the widespread adoption of non-invasive treatments, including next-generation solutions like their planned ultrasonic Deep Brain Stimulator, thereby making advanced therapies more accessible and less burdensome for patients.

High-Level Overview

YektaSonics Inc. develops cost-effective ultrasound beamformers and electronic systems, including phased arrays and power modules, that drive transducers to generate acoustic waves with precise phase and power control for medical and non-medical applications.[1][3][4] The company primarily serves the Focused Ultrasound (FUS) sector, enabling non-invasive treatments for over 180 conditions in oncology, gynecology, neurology, psychiatry, and more, while also addressing engineering uses like fault detection and flow control; its innovations reduce costs and improve performance, positioning it for growth in therapeutics like the ultrasonic Deep Brain Stimulator (uDBS).[1][2][4][5]

With under 25 employees and revenue below $5 million, YektaSonics operates from Richmond, California (with ties to Santa Cruz), focusing on patented electronics that eliminate matching networks, produce harmonic-free outputs, and enable miniaturization.[1][2][3]

Origin Story

Founded in 2017, YektaSonics emerged from expertise in ultrasound technology, led by founder Navid (likely Navid Khodapanah), with advisor Ali Niknejad from UC Berkeley providing guidance on the patented phased array systems.[3][5] The idea stemmed from breakthroughs in low-cost, high-power FUS drivers, building on National Science Foundation (NSF) Phase I funding and university ties, including UC collaborations, to advance non-invasive alternatives to invasive procedures like Deep Brain Stimulation (DBS).[4][5]

Early traction included developing scalable, miniaturized electronics for FUS devices, forging relationships in medical and industry communities, and planning uDBS prototypes to treat neurological conditions like epilepsy and Parkinson's without surgery.[2][5]

Core Differentiators

• Cost-Performance Breakthroughs: Produces pure sine/RF outputs at ultrasound frequencies with fine phase/power control, removing per-transducer matching networks to slash costs while boosting power and scalability.[1][3][4]
• Compact and Versatile Design: Miniaturized boards enable single-channel power modules and multi-channel phased arrays for both medical FUS (treating 180+ conditions non-invasively) and non-medical uses like distance sensing.[2][4]
• Patented Innovations: Harmonic-free signaling, high-power capability, and FUS enhancements position it ahead of competitors, with NSF-backed R&D for uDBS to replace invasive DBS.[1][5]
• Broad Applicability: Targets oncology, neurology, and engineering, offering affordable, high-performance solutions without performance trade-offs.[2][4]

Role in the Broader Tech Landscape

YektaSonics rides the Focused Ultrasound revolution, akin to MRI's impact on diagnostics 40 years ago, by enabling non-invasive therapeutics amid rising demand for surgery-free treatments in neurology and oncology.[4][5] Timing aligns with only 9 FDA-approved FUS indications despite 180+ potentials, fueled by market forces like aging populations needing alternatives to chemotherapy/DBS and cost pressures in medtech.[1][2]

It influences the ecosystem by democratizing FUS access through cheaper electronics, accelerating adoption in startups and hospitals, and bridging hardware with therapeutics via university/NSF ties.[5]

Quick Take & Future Outlook

YektaSonics is primed to launch uDBS and expand phased arrays, capitalizing on FUS growth as approvals multiply and miniaturization enables portable devices.[2][4][5] Trends like AI-enhanced beamforming and non-invasive neurotech will amplify its edge, potentially evolving it from niche innovator to key enabler in a multi-billion medtech market. Watch for partnerships or funding to scale production, solidifying its role in "curing with sound."[4][5]